WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
_256_384.jpg)
The GL 22 Blood Glucose Monitor combines German precision with advanced technology designed to meet local needs
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
The centre features a cutting-edge climatic chamber for stability testing and spectrophotometry to ensure that products meet the most stringent manufacturing and testing standards
The collaboration offers opportunities for training, research fellowships, workshops and conferences at palliative care centers managed by Ajit Isaac Foundation
New research labs and process development services to enable next generation therapeutics
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Modernization and supply chain diversity drive new growth
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Subscribe To Our Newsletter & Stay Updated
